Despite the efficacy of anti-TNF drugs for treatment of rheumatoid arthritis, Crohn’s disease and psoriasis, these drugs block the action of both tmTNF-α and sTNF-α and thus can increase the risk of infection, malignancy and development of secondary autoimmune diseases34. This evidence concerns the gene TNF and Crohn disease.